Article
Author(s):
Washington-As Congress moves toward possible approval of a new prescriptiondrug program for Medicare recipients later this summer, determination ofpayments for cancer drugs and therapeutic services may well hang in thebalance.
Money Matters: 6 financial pitfalls physicians should watch out for
Health policy in urology: 2024 AUA Advocacy Summit recap
Coding Q&A: How to bill for second-generation stone device
How APPs can bridge the gap in urologist shortages
Money Matters: How to cope with market volatility in 2025
How to bill for telephone-only urology visits
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
AI-based tool aims to optimize MRI use in prostate cancer diagnosis
PSMA-PET imaging product, Gozellix, launches on US market
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer